Galectin Therapeutics Inc
$ 2.61
9.66%
11 Jun - close price
- Market Cap 171,886,000 USD
- Current Price $ 2.61
- High / Low $ 2.64 / 2.35
- Stock P/E N/A
- Book Value -2.01
- EPS -0.41
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.80 %
- ROE -37.28 %
- 52 Week High 7.13
- 52 Week Low 1.38
About
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia.
Analyst Target Price
$11.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-15 | 2026-03-31 | 2025-11-14 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-14 | 2024-08-13 | 2024-05-15 | 2024-03-29 | 2023-11-13 | 2023-08-14 |
| Reported EPS | -0.08 | -0.08 | -0.13 | -0.12 | -0.1917 | -0.19 | -0.18 | -0.2 | -0.19 | -0.16 | -0.24 | -0.15 |
| Estimated EPS | -0.06 | -0.1 | -0.18 | -0.19 | -0.11 | -0.16 | -0.2 | -0.16 | -0.16 | -0.16 | -0.16 | -0.21 |
| Surprise | -0.02 | 0.02 | 0.05 | 0.07 | -0.0817 | -0.03 | 0.02 | -0.04 | -0.03 | 0 | -0.08 | 0.06 |
| Surprise Percentage | -33.3333% | 20% | 27.7778% | 36.8421% | -74.2727% | -18.75% | 10% | -25% | -18.75% | 0% | -50% | 28.5714% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GALT
2026-05-28 14:39:34
Jamil Khurram, CMO of Galectin Therapeutics Inc. (GALT), sold $1,761 worth of company common stock on May 26, 2026, after exercising stock options under a Rule 10b5-1 trading plan. The sale involved 568 shares at an average price of $3.1004 per share, following the acquisition of these shares at $1.23 per share through options. Despite a recent stock decline, GALT announced positive NAVIGATE Phase 2b clinical trial results and the appointment of Dr. Henry Brem to its Board.
2026-05-28 13:41:00
Jamil Khurram, CMO of Galectin Therapeutics Inc. (NASDAQ:GALT), sold 568 shares of company common stock for $1,761 on May 26, 2026, following the exercise of stock options. This sale, executed under a Rule 10b5-1 trading plan, occurred despite analysts maintaining a bullish price target of $11 for GALT. The company recently published Phase 2b trial results for belapectin in Hepatology and appointed Dr. Henry Brem as an independent director.
2026-05-28 13:39:34
Jamil Khurram, the Chief Medical Officer of Galectin Therapeutics (GALT), exercised stock options to acquire 568 shares and subsequently sold them at a weighted average price of $3.1004 per share. This transaction was pre-planned under a Rule 10b5-1 trading plan and resulted in him holding no common shares directly, though he still possesses options for 40,057 shares. The filing details the transaction, which occurred on May 26, 2026.
2026-05-19 18:10:14
This article provides details on the number of shareholders for Galectin Therapeutics Inc. (NASDAQ: GALT). It also lists various financial and market data resources available for the company through TradingView. The content primarily focuses on the organizational structure and data sources rather than specific shareholder numbers.
2026-05-16 17:09:18
Galectin Therapeutics reported its first-quarter research and development expenses were $2.2 million. This financial detail is key for investors monitoring the company's operational spending. The information is relevant for those following GALT.
2026-05-16 13:40:20
Galectin Therapeutics filed its 10-Q for Q1 2026, reporting no consolidated revenue, net income, or diluted EPS. The company highlighted clinical progress for its lead candidate, belapectin, for MASH cirrhosis, including results from the NAVIGATE Phase 2b study. Following the study's completion, R&D activity and headcount were reduced to lower cash burn, and a Type C meeting with the FDA is scheduled to discuss future development.
